The MaxCyte STX Scalable Transfection System to be Launched at the SBS Symposium on Cell-Ba...(STX Scalable Transfection System. Abo...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
The MaxCyte STX Scalable Transfection System to be Launched at the SBS Symposium on Cell-Based Assays
Date:10/22/2008
STX Scalable Transfection System.
About MaxCyte
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. The MaxCyte transfection technology was originally developed as an enabling technology for cell therapy and is currently being used in a number of clinical trials around the world. Drawing upon this expertise in cell loading for cell therapy, MaxCyte introduced this transfection technology into drug discovery applications as the MaxCyte STX Scalable Transfection System. The MaxCyte STX allows for the rapid, scalable, and reagent-free cell transfection for cell based assays, preclinical protein production, and other cell-based applications.
For more information, http://www.maxcyte.com/cell-based-screening.shtml
'/>"/>
| SOURCE MaxCyte, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. MaxCyte and Medinet to Present at the 10th International Symposium on Dendritic Cells in Kobe, Japan
2. MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting
3. MaxCyte to Present at BIO-Europe Spring 2008 Conference
4. Binex and MaxCyte Collaborate on Cancer Immunotherapy Research
5. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
6. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
7. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
8. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
9. Enigma Diagnostics Announces Patent Licence With Applied Biosystems
10. First CyberKnife System Purchased in Latin America
11. Perceptive Informatics Improves Efficiency and Clinical Data Quality With Enhanced Version of EDC System
Post Your Comments:
Breaking Biology Technology:Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5
[0] For Release: Esco Announces 2nd North American Facility in Marietta, OH [0] Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference[0] Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products[0] YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
Other Biology Technology:SleepQuest Compliance Again Doubles Industry Average 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 3Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 4AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences 2AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences 3
Breaking Biology News(10 mins):Roe of marine animals is best natural source of omega-3 2Space agencies join forces to systematically observe climate variables 2Space agencies join forces to systematically observe climate variables 3Kornberg Associates | Architects Completes UC Riverside Stem Cell Core Facility Project 2Kensey Nash to Present at the Jefferies 3rd Annual Healthcare Conference 48487 1Anthropedia Foundation Charity Gala Murten Switzerland in the Presence of HSH Prince Albert II of Monaco 48483 1Anthropedia Foundation Charity Gala Murten Switzerland in the Presence of HSH Prince Albert II of Monaco 48483 2Latest trinational report presents most complete picture of North American industrial pollution 48480 1Latest trinational report presents most complete picture of North American industrial pollution 48480 2Latest trinational report presents most complete picture of North American industrial pollution 48480 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |